Critical limb ischemia (CLI), defined as ischemic rest pain or the presence of a nonhealing arterial ulcer or gangrene, is the most advanced and debilitating form of peripheral artery disease (PAD). An estimated 10% of patients with PAD progress to CLI within 5 years, with the annual incidence of CLI ranging between 500 and 1,000 new cases per 1 million individuals (1). Within 3 months from the time of diagnosis, 9% of CLI patients will die and 12% will require major amputation. One- and 2-year mortality rates of 21% and 31.6% have been reported (1). Collectively, CLI substantially affects patient quality of life and exerts a substantial economic burden to the overall health care system (1,2).